Data are available from the Data Governance Board of the Máxima Medical Centre for researchers who can demonstrate that they are qualified to use confidential data. A request can be addressed to the corresponding author (<carlijn_lempersz@hotmail.com>) or the Data Governance Board at the Máxima Medical Centre (J. Luime, <j.luime@mmc.nl>).

Introduction {#sec005}
============

The fetal heart in mid-pregnancy is one of the most difficult organs to examine during the standard anomaly scan. The assessment is made difficult due to the small size of the fetal heart, its movement, and its complicated anatomy. In addition, maternal body mass index highly influences interpretability. Taking all this into consideration, a successful assessment of the heart is highly dependent on the skill of the sonographer.\[[@pone.0232606.ref001]\]

The timely prenatal detection of CHD has some important advantages. In the case of severe defects parents may choose to terminate the pregnancy. Where the pregnancy is continued, a prenatal diagnosis of CHD allows the parents time to prepare for the arrival of their sick child. Furthermore, it facilitates appropriate changes in obstetric and neonatal management, including intra-uterine therapy, planning of the delivery in a center with the required neonatal and cardiothoracic surgical care facilities, and timely treatment after birth. It has been demonstrated that prenatal diagnosis of CHD increases survival rates and decreases long-term morbidity. \[[@pone.0232606.ref002]--[@pone.0232606.ref006]\]

An additional tool for the assessment of the fetal heart in mid-pregnancy that is less dependent on human experience and interpretation is desirable. This tool could be the fetal electrocardiogram. Electrocardiography is used worldwide as a relatively simple tool to assist in the diagnosis of heart disease in adults and children as well as in the diagnosis and management of arrhythmias.

Until now, it has not been possible to record a reliable standard non-invasive fetal ECG for fetal heart assessment. Inter- and intra-fetal comparisons are hampered since the fetus is free to move underneath the transabdominal electrodes and thereby can take any orientation with respect to the electrodes. Hence, standardization of the fetal ECG, i.e. normalizing for the fetal orientation, is needed to allow fetal ECG waveform analysis. A published standardization method is currently not available. \[[@pone.0232606.ref007]\] Moreover, very little is known about what constitutes a normal fetal ECG at around 20 weeks of gestation.

In this paper, we present a method for standardization of the fetal ECG that was applied to a cohort of more than 300 fetuses to show the feasibility of recording a standardized fetal ECG in mid-pregnancy. Furthermore, we compared the normal ECG to the ECGs of two fetuses prenatally diagnosed with congenital heart disease (CHD) to illustrate the potential value of fetal ECG for CHD screening and diagnosis in mid-pregnancy and discuss the possible future applications of the fetal ECG.

Materials and methods {#sec006}
=====================

Ethics statement {#sec007}
----------------

The study was approved by the Máxima Medical Centre institutional review board (NL48535.015.14). Participants were included in the study after written informed consent had been obtained.

This study was part of a larger ongoing entity, consisting of a healthy cohort and a group of fetuses with known congenital heart disease (CHD).This trial is registered at the Netherlands Trial Register (NTR5906). The study protocol has been published by Verdurmen et al. \[[@pone.0232606.ref008]\] The study was approved by the Máxima Medical Centre institutional review board (NL48535.015.14). Fetal ECG measurements were performed between May 2014 and February 2017 at the Máxima Medical Centre, Veldhoven, The Netherlands and at 'Diagnostiek voor U' diagnostic center, Eindhoven, The Netherlands. Measurements were performed directly before or after the 20-week fetal anomaly scan. This anomaly examination was performed by a certified and experienced ultrasonographist. Three months after birth, the participants received a questionnaire to verify that the child was healthy and did not have CHD. This three month time interval was chosen because in The Netherlands every newborn will have several general check-ups by a primary healthcare doctor within three months after birth.

Women with an uneventful pregnancy, carrying a singleton fetus with a gestational age between 18 and 24 weeks, were included in the study after written informed consent had been obtained. The included pregnant women had to be older than 18 years of age. Fetuses with diagnosed CHD were excluded. Other exclusion criteria were multiple pregnancies, insufficient understanding of the Dutch language, and any known fetal congenital anomalies other than CHD. If the fetus turned out to have a CHD later in pregnancy or postnatally, it was subsequently excluded from further analysis.

To illustrate the potential of fetal electrocardiography for CHD screening, the normal ECG was compared to the ECG of two fetuses prenatally diagnosed with different CHDs. These ECG recordings were performed in the Amsterdam University Medical Center, Amsterdam, the Netherlands and approved by the medical ethics committee of the Amsterdam University Medical Center (2015_221\#A201583).

The fetal ECG was recorded with adhesive Ag/AgCl electrodes on the abdomen of the pregnant women in a semi-recumbent position. In total, eight electrodes were placed on the abdomen in a fixed configuration (see [Fig 1](#pone.0232606.g001){ref-type="fig"}) in order to yield six channels of bipolar electrophysiological measurements: the other two electrodes served as common reference and ground. Application of the device is comparable to a regular ECG device and takes no more than 5 minutes. For research purposes, the duration of the registration was approximately 30 minutes, during which the fetal position was determined four times by ultrasound assessment. The determination of the fetal position typically took 10--20 seconds. After a short instruction during one measurement medical students were able to perform the measurements and the fetal orientation ultrasounds without supervision.

![Measurement setup.\
Measurement setup with eight electrodes on the maternal abdomen (six recording electrodes, one common reference (ref), one ground (gnd)) and the prototype fetal monitoring system. The bipolar channels are indicated by the arrows and formed by the electrodes 1--6 with respect to the common reference (eg 1 --ref, 2 --ref). The positions of the electrodes and lead vectors of the recorded channels are defined within the xyz-axis system depicted on the bottom right.](pone.0232606.g001){#pone.0232606.g001}

The electrophysiological signals were digitized and stored at 500 Hz sampling frequency by a prototype fetal monitoring system (Nemo Healthcare BV, the Netherlands) to enable analysis in a later stage. After digitization, the acquired signals were processed by PC-based signal processing techniques as previously described by Vullings et al. \[[@pone.0232606.ref009], [@pone.0232606.ref010]\] and Warmerdam et al. \[[@pone.0232606.ref011]\], as illustrated in [Fig 2](#pone.0232606.g002){ref-type="fig"}.

![Schematic illustration of signal processing to obtain standardized fetal ECG.\
Schematic illustration of signal processing steps followed to obtain the standardized fetal ECG. From the top left, the consecutive steps are depicted in a clockwise direction. In the first step the raw data was filtered to suppress the maternal ECG. In the next step, the fetal ECG was further enhanced by averaging the ECG over 30 heartbeats. Multi-channel ECG complexes were subsequently combined to calculate the vectorcardiogram (VCG). This VCG is described within a coordinate system (xyz) that is defined with respect to the maternal body. Based on the fetal orientation assessed by ultrasound examination, a mathematical rotation **R** of the VCG was performed to convert the VCG to a coordinate system (x'y'z') that is defined with respect to the fetal body. Finally, the rotated VCG was transformed with the Dower matrix to yield an estimate for the standardized, 12-lead fetal ECG.](pone.0232606.g002){#pone.0232606.g002}

The first step in the process was the suppression of interferences such as the maternal ECG, powerline interference, and electromyographic signals from within the maternal body, using a template-based subtraction technique \[[@pone.0232606.ref010]\], a Kalman smoother \[[@pone.0232606.ref011]\], and a bandpass filter\[[@pone.0232606.ref010]\], respectively. The fetal QRS complexes were then identified using a method described in Warmerdam et al. \[[@pone.0232606.ref012]\] Subsequently, the fetal ECG signals were segmented in such a way that every segment contained exactly one heartbeat. The length of the segments was defined as mean RR interval (i.e. inter-beat interval) of the particular recording/fetus. The start of each segment was defined such that the R-peak was located at 40% of the segment length. As a consequence, all segments were synchronized on the position of the R-peak.

The QRS detection method of Warmerdam et al. \[[@pone.0232606.ref012]\] was used to check whether a detected fetal QRS complex was correct or not. This system uses various checks: the interval between successive QRS complexes (i.e. RR-interval) should be in line with the physiological range of the fetal heartbeat (i.e. between 60 and 240 beats-per-minute) and cannot vary more than 20% between consecutive RR-intervals. Moreover, the morphology of the QRS complexes should be similar between consecutive heartbeats, their energy not be higher than physiologically plausible, and they should not coincide for more than three consecutive heartbeats with the ECG of the mother. The latter criterion was used to prevent the erroneous detection of maternal ECG residues as fetal QRS complexes. When a detected fetal QRS complex did not confirm to all these criteria, it was rejected and excluded from further analysis. We used an average of at least 25 detected fetal QRS complexes per minute as threshold for signal quality. Where this threshold was not met, the entire recording was excluded from further analysis due to low signal quality.

Where the signal quality was assessed as adequate, we enhanced the fetal ECG further by averaging 30 consecutive segments. This procedure was performed for each of the six channels of fetal ECG data.

As mentioned previously, before we could compare ECG waveforms between patients, the ECG needed to be normalized for the fetal orientation. Without such normalization, a specific electrode would record a different ECG waveform for, for example, a fetus in a cephalic position versus the same fetus in a breech position. To normalize for fetal orientation, we first calculated the vectorcardiogram (VCG) of the fetus. \[[@pone.0232606.ref009]\] This VCG entailed a three-dimensional representation of the fetal electrical cardiac activity, in other words the path of electrical cardiac activation through the heart. The VCG was calculated for each average ECG (i.e. the ECG obtained from averaging 30 consecutive segments). At this point, the fetal VCG was determined in the xyz-coordinate system that was described with respect to the maternal body (see [Fig 1](#pone.0232606.g001){ref-type="fig"}, bottom right). In order to facilitate interpretation and standardization of this fetal VCG, it must be placed within a coordinate system that is described with respect to the fetal body. The mathematical rotation that defines this conversion between coordinate systems could be calculated based on an ultrasound assessment of the fetal orientation.

Furthermore, the expectation-maximization algorithm was used to track rotations of the VCG between heartbeats due to fetal movements between the ultrasound assessments ([Fig 3](#pone.0232606.g003){ref-type="fig"}). \[[@pone.0232606.ref013]\] Based on the tracked VCG rotations, we corrected for these fetal movements, using similar mathematical rotations as used for the correction of the fetal orientation. The four ultrasound assessments during the measurements were used to correct for cumulative errors in this movement correction method and to determine the initial orientation of the fetus. After correcting for fetal movements, the VCGs throughout the entire recording were averaged to further enhance signal quality.

![Rotation of the VCG between heartbeats due to fetal movement.\
In black the VCG at time t = 0, in red the VCG at time t = 1. Due to fetal movement there was a rotation of the VCG.](pone.0232606.g003){#pone.0232606.g003}

Because clinicians are not used to interpreting a VCG, we chose to visualize the fetal cardiac activity by means of a 12-lead ECG. As described by Dower \[[@pone.0232606.ref014]\], in adult electrocardiography the VCG can be used to calculate standardized ECG leads. In this study, we used the Dower transformation \[[@pone.0232606.ref015]\] to calculate a 12-lead ECG from the VCG for each fetus.

The segmentation of the fetal ECG data described above depended on the fetal heart rate during the recording: the length of the segments was defined as the mean RR interval of the fetus during the recording. Because different fetuses have different heart rates, the calculated standardized ECG leads had different lengths across the fetuses. To enable comparison between fetuses, we calculated the average RR interval over all fetuses: in this case a length of 0.44s. Next, we resampled all standardized ECG leads to match this length. As, the R-peak was located at 40% of the segment length for each fetus, after resampling to the uniform segment length of 0.44s, the R-peaks for all fetuses were still at 40% and hence synchronized over all standardized ECG leads.

To assess whether a standardized fetal ECG is feasible, we determined the median amplitude and interquartile range (IQR) for all fetuses with adequate signal quality to yield a median ECG waveform.

Results {#sec008}
=======

Normal hearts {#sec009}
-------------

During the study period, informed consent was obtained from 328 participants and a fetal ECG was performed. 37 measurements were excluded from further analysis because we did not receive a postpartum questionnaire (n = 14) or because there was no fetal orientation ultrasound available (n = 23). In addition two children appeared to have a CHD and three children were diagnosed with a syndrome and were excluded from further analysis. Of the final 286 recordings, 281 were of adequate quality to generate a standardized fetal ECG, yielding a success rate of 98.3%.

The number of detected QRS complexes in the recordings with sufficient quality ranged from 35 to 156 complexes per minute and from 565 to 6130 detected complexes over the full recording.

[Fig 4](#pone.0232606.g004){ref-type="fig"} shows the median ECG waveform for leads I (left) and aVF (right) in black, with in grey the IQR for the included 299 fetuses.

![Normal ECG waveform.\
Normal ECG waveform with in black the median over 281 healthy fetuses and in grey the interquartile range, shown for lead I (A) and lead aVF (B).](pone.0232606.g004){#pone.0232606.g004}

In [Fig 5](#pone.0232606.g005){ref-type="fig"} the median 12-lead ECG is shown.

![12-lead normal fetal ECG in mid-pregnancy.\
12-lead ECG of the normal fetal heart at 20 weeks of gestation, calculated as the median over 281 healthy fetuses. Note the rightward QRS axis and the right ventricular dominance (positive R wave in V1 with deep S in V6 and failure of R wave progression precordially). The marker on the bottom left indicates the scale at which an amplitude of 1 μV is depicted.](pone.0232606.g005){#pone.0232606.g005}

From all the figures, it can be seen that the median ECG waveform indicates an electrical heart axis oriented right inferiorly, based on the negative QRS deflection in lead I and the positive deflection in lead aVF. This suggests a dominant right ventricle, which is in line with the higher cardiac output (volume loading) and pressure loading of this ventricle in-utero. \[[@pone.0232606.ref016]--[@pone.0232606.ref019]\]

Congenital heart disease {#sec010}
------------------------

### ECGs were recorded from two fetuses diagnosed with CHD {#sec011}

The first patient was diagnosed at 21+2 weeks of gestation with left atrial isomerism (mesocardia, bilateral superior caval veins and polysplenia) and complete atrio-ventricular septal defect (AVSD) with left ventricular dominance. The fetal ECG registration was made at 26+3 weeks of gestation. Postnatally, this baby died suddenly from a group B streptococcal septicemia and the cardiac diagnosis was confirmed at post mortem examination.

The second patient was diagnosed at 16+4 weeks of gestation with a hypoplastic right ventricle, tricuspid stenosis and a dysplastic pulmonary valve (hypoplastic right heart). The fetal ECG registration was made at 20+6 weeks of gestation. The diagnosis was confirmed by post mortem examination after termination of the pregnancy.

In [Fig 6](#pone.0232606.g006){ref-type="fig"}, the ECG of the fetus with left atrial isomerism and AVSD can be seen. The QRS axis is abnormal (-45 degrees) and there is a prominent left ventricle. In [Fig 7](#pone.0232606.g007){ref-type="fig"}, the ECG of the fetus with the hypoplastic right heart (a ductal dependent lesion) is depicted. The QRS axis is abnormal (+60 degrees) and there is left ventricular dominance, based on the prominent R waves in V5 and V6.

![12-lead fetal ECG of left isomerism and atrioventricular septal defect.\
12-lead ECG of case 1 with the atrio-ventricular septal defect: Note the abnormal QRS axis (-45 degrees) and prominent left ventricle (prominent R in V5 and V6 and deep S in V1 and V2 as well as the negative aVR). The marker on the bottom left indicates the scale at which an amplitude of 1 μV is depicted.](pone.0232606.g006){#pone.0232606.g006}

![12-lead fetal ECG of hypoplastic right heart.\
12-lead ECG of case 2 with a hypoplastic right heart (hypoplastic right ventricle, tricuspid stenosis and dysplastic pulmonary valve): Note the abnormal QRS axis (+60 degrees) and left ventricular dominance (prominent R waves in V5 and V6). The marker on the bottom left indicates the scale at which an amplitude of 1 μV is depicted.](pone.0232606.g007){#pone.0232606.g007}

To illustrate the difference between these two cases and the normal fetal ECG, in [Fig 8](#pone.0232606.g008){ref-type="fig"} the ECGs of the CHD cases are overlayed on the IQR of the normal for leads I and aVF.

![ECG of cases compared to normal ECG.\
Leads I (A) and aVF (B) for the two CHD cases, plotted together with the IQR of the normal ECG. The gray area represents the IQR of the normal ECG, the solid line represents the fetus with atrio-ventricular septal defect ([Fig 6](#pone.0232606.g006){ref-type="fig"}) and the dashed line represents the fetus with hypoplastic right heart ([Fig 7](#pone.0232606.g007){ref-type="fig"}).](pone.0232606.g008){#pone.0232606.g008}

Discussion {#sec012}
==========

For the first time, we have presented the feasibility of a method for estimating a standardized 12-lead ECG for a healthy fetus around 20 weeks of gestation in which we used ultrasound assessment of the fetal orientation to correct for its influence on the estimated fetal ECG.

When compared to other organs examined during the 20-week anomaly scan, screening of the fetal heart with ultrasound imaging is regarded as the most difficult due to its motion, small size and anatomical complexity. Therefore, CHD in the mid-term fetus is often missed. \[[@pone.0232606.ref020], [@pone.0232606.ref021]\] This is especially undesirable because it has been demonstrated that prenatal diagnosis of CHD increases neonatal survival rates and decreases neonatal long-term morbidity. \[[@pone.0232606.ref004]--[@pone.0232606.ref006], [@pone.0232606.ref022], [@pone.0232606.ref023]\] The performance of a fetal ECG could aid screening for CHD in mid-pregnancy in primary care and follow-up in dedicated centers, since it is independent of the experience of the sonographer, difficult fetal imaging due to maternal obesity, an unfavorable fetal position, or reduced amniotic fluid. The fetal ECG might also give more information about the evolution of the CHD during pregnancy and, with that, the health status of the fetus. Although there is no reference to compare our results with, our results show the reproducibility of the 'mean' ECG in all 281 participating fetuses. Furthermore, it can be seen that the standardized ECG has, conform expectations, a right ventricular dominance e.g. a right oriented electrical heart axis. The electrical heart axis represents the median vector of the electrical activity through the heart during one cardiac cycle and gives information about the muscle distribution of the heart. CHD may alter this distribution. The electrical heart axis could thus be a potential indicator for CHD in mid-pregnancy.

The potential use of the fetal ECG in CHD screening was further illustrated by the examination of ECG recordings from the two cases with CHD (Figs [6](#pone.0232606.g006){ref-type="fig"} and [7](#pone.0232606.g007){ref-type="fig"}). Both cases showed ECG abnormalities (e.g. abnormal QRS axis) when compared to the IQR of the normal ECG ([Fig 8](#pone.0232606.g008){ref-type="fig"}).

In the first CHD case, left atrial isomerism with AVSD, there was an abnormal axis due to the altered cardiac conduction system anatomy (causing a left anterior hemi-block) and left ventricular hypertrophy due to the atrio-ventricular valve regurgitation in utero. This case died unexpectedly of septicemia as a neonate but had this not occurred, we would have expected the baby to develop cardiac failure from around two weeks of age and she would have required a complete surgical correction before the age of three months. Case two was a ductal dependent lesion where a prenatal detection is extremely important to ensure the timely postnatal administration of intravenous prostaglandins to keep the arterial duct open. Failure to do so could be life-threatening due to inadequate pulmonary perfusion resulting in acidosis, organ failure, neurological damage and death. Both cases could have been detected by fetal ECG screening.

The high success rate of 98.3% shows the promise of a reliable additional tool for clinical practice, which may be less subject to human interpretation and experience. Besides signal quality, the applicability of this method also depends on the availability to estimate the fetal orientation (e.g. from simultaneous ultrasound examination). Without accurate information on the fetal orientation, normalization for this orientation is not possible and analysis of the fetal ECG has to be limited to the analysis of ECG intervals.

Limitations {#sec013}
-----------

The signal analysis methods that were used in our study to enable standardization of the fetal ECG have four main limitations. First, in the calculation of the VCG, information of the amplitude of the fetal ECG and VCG was lost, because the distance between the fetal heart and each of the transabdominal electrodes is different. The thickness of the layers of maternal tissue in between the fetal heart and the electrode varies between the different electrodes and therefore, attenuation of the ECG signal due to conduction of the signal from the heart to electrode will be different for each electrode. Our method for VCG calculation can compensate for such variations in attenuation, but only with normalization of all amplitudes. Besides compensating for inter-electrode differences in ECG signal attenuation, this method has the capacity that inter-patient variations in ECG signal attenuation are also compensated for. Such inter-patient variations could originate from differences in BMI, amount of amniotic fluid, distribution of muscle and fat tissue in the abdomen, and properties of the skin. Second, the calculation of the 12-lead ECG from the VCG via the Dower matrix is based on assumptions about geometrical and conductive properties of the adult thorax that may not fully apply to the fetal thorax. Interpretation of the fetal ECG should therefore not be based on guidelines used for 12-lead adult ECG. The third limitation is that to further enhance signal quality, averaging over 30 segments (i.e. heartbeats) took place. This entails a trade-off between gain in fetal ECG signal quality and loss of inter-beat variability in the ECG. The gain in signal quality allows for possible diagnosis of structural malformations of the heart, but the concomitant loss of inter-beat variability hampers arrhythmia diagnosis.

Averaging over multiple heartbeats emphasizes the part of the ECG that is common between heartbeats. Structural malformations will affect every heartbeat in more or less the same way and hence be visible in the average ECG. The fourth limitation is that the data was evaluated retrospectively. However, pseudo real-time implementations (i.e. only a few seconds delay) of the described technology are being developed.

Future research should focus on defining normal ranges and values for the fetal ECG in mid-pregnancy, including the electrical heart axis. When normal ranges and values are established research could focus on the application of the fetal ECG for the detection and follow-up of fetal heart disease. An abnormal fetal ECG may expedite a referral for an advanced fetal echocardiogram in dedicated centers in the future.

Conclusion {#sec014}
==========

To conclude, we demonstrated that it is possible to determine a fetal ECG for a healthy fetus at 20-weeks of gestation and standardize this ECG for the fetal orientation. As a result, we have presented the first standardized ECG for a healthy 20-week fetus.

To illustrate the clinical relevance of this standardized fetal ECG, we showed that the standardized ECG thus derived is clearly different from 2 cases with congenital heart disease. Although the recording of a 12-lead fetal ECG is feasible with non-invasive fetal ECG technology, more research is needed to study its implications for clinical practice.
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3\. It\'s known that the predominance of right ventricle activity is typical during fetal life in a healthy pregnancy. Where is the border between health and pathology in her projections on fetal vector ECG?

Reviewer \#2: Overall the research idea and number of recordings collected is significant, however, there are several factors that greatly decrease the quality of the article. The structure is quite confusing and the reader sometimes feels lost. In some parts (chapter Materials and Methods) the authors supply the reader with a lot of details that are not necessary (or could be summarized using e.g. a Table) whereas some important information is missing.

Line 216 and 304 -- You state that the success rate was 98.87 %. What did you use for the comparison? There is no reference mentioned. Furthermore, you state that "there is no reference to compare our results with" (line 281).

Line 217-218 -- you mentioned that the number of detected QRS complexes in the recordings with sufficient quality ranged from 35 to 156 complexes per minute and from 565 to 6130 detected complexes over the full recording. Again, is there any reference annotation by the experts? Or how do you differentiate between the fetal QRS complexes in the accurately extracted signal from e.g. the maternal residue in the signals extracted poorly?

The above mentioned is either not defined at all or it is described very poorly (e.g. lines 146-157) so it is very hard to follow the research process. I guess the flowchart in the last figure was created to help in this matter, but I personally find it more misleading than helpful.

What I am really confused from the most is the Conclusion. It includes only 3 sentences and states something else that what my idea about the article was. In Results you mention that you recorded 328 fECGs and analyzed 281 from it. However, in the Conclusion it seems like you presented a single ECG for 20-week fetus and then compared a mean ECG thus derived with 2 cases with congenital heart disease. So this article a case study??

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Igor V. Lakhno

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear editor and reviewers,

First we would like to thank you and the journal for considering our work for publication in PLOS ONE. We have carefully considered the reviewers' remarks and adjusted the manuscript accordingly. For our response to the comments we would like to refer to the text below. For your and the reviewers' convenience, any changes to the text that were made in response to the reviewers' comments are highlighted in the redline version of the manuscript.

Reviewer \#1.

The study is well-designed and the paper is well-written. The feasibility to obtain fetal non-invasive ECG before 26 weeks of gestation is known (lack of vernix caseosa). The manuscript contains a piece of novel information on fetal non-invasive ECG as a screening method for fetal cardiac malformations. The authors have used vector ECG as a main diagnostic tool. The results are promising. I have not found any principal shortcomings. My recommendation is to accept.

Thank you for your positive evaluation of our manuscript.

I have several questions.

1\. What is the best term for fetal non-invasive ECG screening?

The best term is between 20-22 weeks of gestation. In this study, we found good signal quality from the 20th week of gestation. Furthermore, when screening for congenital heart disease it is important to screen as early as possible. This gives parents the chance to make an unrushed decision as to whether to continue with the pregnancy or not should severe congenital heart disease be detected. Where the pregnancy is continued, preparations in dedicated centres can be made to give optimal care for mother and child. Changes in the introduction have been made where this is addressed.

2\. Have you found fetal non-invasive ECG intervals and peaks measurement feasible for clinical interpretation?

Due to averaging of the fetal ECG over multiple heartbeats we found that some information regarding possible variations in ECG intervals is lost. In the averaged ECG complexes, QRS complexes and often also P-waves can be identified; T-waves appear to be more challenging, probably due to the effect of the tissues between the fetal heart and the abdominal electrodes. These tissues are known to suppress low-frequency waves, such as the T-wave. More research regarding interval analysis is needed and is a subject we hope to address in the near future.

We think, that analysis of the peak amplitudes is possible, under the constraint that we have to compare amplitudes relative to each other, for instance T/QRS ratios. Due to inter- and intra-patient variations in the position of the fetus and its proximity to the abdominal electrodes, the amplitude of the recorded ECG might vary, complicating inter-patient comparisons in absolute peak amplitudes. This is now better explained in the Discussion section of the manuscript.

3\. It's known that the predominance of right ventricle activity is typical during fetal life in a healthy pregnancy. Where is the border between health and pathology in her projections on fetal vector ECG?

This border is not defined yet. We are working with this dataset to define normal ranges for the electrical heart axis in healthy fetuses in mid-pregnancy. Then we will compare those results with the electrical heart axis found in fetuses with a known congenital heart disease to indeed search for such border. The answer to this question is added in the Discussion section of the manuscript.

Reviewer \#2

Overall the research idea and number of recordings collected is significant, however, there are several factors that greatly decrease the quality of the article. The structure is quite confusing and the reader sometimes feels lost. In some parts (chapter Materials and Methods) the authors supply the reader with a lot of details that are not necessary (or could be summarized using e.g. a Table) whereas some important information is missing.

Thank you for your feedback and questions to help us clarify the study and its results better. We have changed the methods (see marked changes) to try make them more clear.

1\. Line 216 and 304 -- You state that the success rate was 98.87 %. What did you use for the comparison? There is no reference mentioned. Furthermore, you state that "there is no reference to compare our results with" (line 281).

The success rate is defined as the percentage of recordings with sufficient quality for further analysis. The definition of "sufficient quality" is defined in the manuscript. Indeed, in antepartum fetal ECG measurements, there is no reference measurement to validate the detected fetal ECG. Hence, we used quality criteria that include the interval between detected fetal QRS complexes (should be comparable between beats) and their morphology (amplitude should not be too large to be physiological). This is stated in the methods section. From the 286 recordings used in our study, 281 were of sufficient quality for further analysis. This is 98.3% of the recordings. The definition of quality has been described more clearly in the Materials and Methods section of the manuscript.

2\. Line 217-218 -- you mentioned that the number of detected QRS complexes in the recordings with sufficient quality ranged from 35 to 156 complexes per minute and from 565 to 6130 detected complexes over the full recording. Again, is there any reference annotation by the experts? Or how do you differentiate between the fetal QRS complexes in the accurately extracted signal from e.g. the maternal residue in the signals extracted poorly? The above mentioned is either not defined at all or it is described very poorly (e.g. lines 146-157) so it is very hard to follow the research process. I guess the flowchart in the last figure was created to help in this matter, but I personally find it more misleading than helpful.

Because we included almost 300 recordings of about 20 minutes each in our dataset, the number of fetal QRS complexes probably exceeded 750.000 which is too laborious to validate by expert referees and as such prone to error. We used criteria mentioned in our reply to the comment above to verify whether a detected QRS complex is indeed a QRS complex. This methodology has been validated and described in more detail in Warmerdam et al. (1). These criteria also include that the detected fetal QRS complexes should not coincide for more than a few beats with the detected maternal QRS complexes. If this were to happen, indeed the detected fetal QRS complexes might be a residue of the maternal ECG and should be excluded from further analysis.

We have adapted the manuscript to describe our quality assessment in more detail.

3\. What I am really confused from the most is the Conclusion. It includes only 3 sentences and states something else that what my idea about the article was. In Results you mention that you recorded 328 fECGs and analyzed 281 from it. However, in the Conclusion it seems like you presented a single ECG for 20-week fetus and then compared a mean ECG thus derived with 2 cases with congenital heart disease. So this article a case study??

As stated in the introduction, our main goal was to investigate if it is possible to produce a standardized fetal ECG. For the 281 fetuses included in our analysis (i.e. those with sufficient signal quality) we analysed whether there it is indeed possible to standardize the ECG measurement by correcting for the fetal orientation. Based on our results, we can conclude that the fetal ECGs, after correction for orientation, look very similar and that the inter-patient correspondence is equivalent to that of healthy newborn ECGs.

To illustrate the potential of this technology for e.g. differentiating between healthy fetuses and those with congenital heart disease (CHD), we presented two cases of CHD to show that indeed these seem very different from the standardized ECG of a healthy fetus. This standardized ECG was determined as the median over all healthy fetuses, similar as one would describe the standard ECG in a healthy adult.

To describe our primary goal better, we have modified the conclusion.
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Dear Dr. Lempersz,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Leticia Reyes

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I think that your paper is focused on a very considerable issue in perinatal medicine. You have found a novel approach to the diagnosing of fetal cardiac malformations. The results look sound.

Reviewer \#2: Dear authors,

Thank you for addressing my comments, great work! My recommendation is to Accept. Good luck in your future research!
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Igor V. Lakhno

Reviewer \#2: Yes: Ing. Radana Kahankova, PhD
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